News About: Pharm. Industry
Hanmi Pharm jumps into an approx. KRW 140 billion market of chronic hepatitis B treaments
Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) will jump into the market of chronic hepatitis B treatments containing tenofovir, which forms a market of approximately KRW 140 billion a year.
After acquiring commercial...
KOSDAQ listed pharmas outnumbers in operating profit increase rate and operating profit/sales ratio
The KOSDAQ listed pharmaceutical companies’ operating profit in/decrease rate was 4 times higher than the one of KOSPI listed pharmaceutical companies in the 1st half of the year compared to the same period of the las...
Listed pharmas cashable assets closed to KRW 2 trillion
Cashable assets listed pharmaceutical companies owned were estimated to reach KRW 2 trillion.
Yakup Shinmoon(www.yakup.com) analyzed 60 KOSPI and KOSDAQ listed pharmaceutical companies’ 2017 2nd quarter reports, and ...
5 listed pharmas can’t even pay interest payable from earnings
5 listed pharmaceutical companies including Cho-A Pharm and Samsung Pharm were observed to be financially difficult to even pay interests of their debts from earnings, showing a poor ability to pay debts.
6 companies...
Rapid increase of bioequivalently recognized medicines due to expiration of originals like Tamiflu and Talion
An enormous number of generic drugs have been launched after patent expiration of original products like Tamiflu and Talion. Thus, there are more medicines recognized by bioequivalent test in the 2nd half of the year....
Hanmi’s ‘Rosuzet’ records highest sales growth rate in 1st half among Korean medicines with more than KRW 10 billion sales
Among Korean pharmaceutical companies’ products which record more than KRW 10 billion sales, a product which had the highest growth rate in the 1st half of the year was Hanmi Pharm’s ‘Rosuzet.’
According to an analys...
SK Chemicals passes preliminary examination for re-listing after spinoff
The Korea Exchange’s securities market headquarters announced on the 22nd that SK Chemicals passed a preliminary examination for re-listing after creating a spinoff.
SK Chemicals is planning to divide its business in...
Novartis rebate trial starts witness examination about reports to CEO
The Novartis’s rebate trail has actively started. It now started to verify details to check if the company shared reports about provision of rebates.
The Seoul Western District Court Criminal Department 5(Judge Deuk-...
Celltrion carries out process to transfer from KOSDAQ to KOSPI
Celltrion held a board meeting on the 21st and resolved to have an extraordinary general meeting to discuss about a change of stock market. The meeting is scheduled to be placed at Songdo Convensia in Incheon at 10am ...
2 of 3 listed pharmas recording operating profit/sales ratio less than 10%
It was observed 2 of 3 listed pharmaceutical companies had an operating profit/sales ratio less than 10%, and there were also 10 companies recording less than 3% that is close to a level of pharmaceutical distribution...
